MAP2K7 and melanoma: Melanoma patients suffering from V600-mutant melanoma showed improved results upon combination therapy (BRAF inhibitor plus MEK inhibitor, e.g., vemurafenib plus cobimetinib, dabrafenib plus trametinib, and encorafenib plus binimetinib) compared with the corresponding BRAF inhibitor monotherapy[32,33].